Synagis palivizumab 100mg/1 mL Single-Dose Vial
How to Order:
You will receive instructions on how to create an account along with Rx Ordering Details.
(Note: Acceptable licenses must have Prescriptive Authority in the license issuing state.)
Cart subtotal
Synagis is the only FDA-approved monoclonal antibody to help protect high-risk infants against RSV.
Synagis palivizumab 100mg/1 mL Single-Dose Vial is a highly effective medication used to prevent serious respiratory infections in infants and young children caused by the respiratory syncytial virus (RSV). RSV is the most common cause of bronchiolitis and pneumonia in children under the age of one, making it a significant health concern for parents and healthcare providers. Synagis works by targeting the RSV virus and preventing it from replicating, therefore reducing the risk of severe lung infections. This medication has been shown to significantly reduce hospitalizations and even deaths in premature infants and children with lung or heart conditions. Its convenient single-dose vial form makes it easy to administer and its recommended dosage of once a month for a total of 5 doses during RSV season offers excellent protection. The benefits of Synagis palivizumab 100mg are clear, as it not only protects against potentially life-threatening infections, but also provides peace of mind for parents knowing their child is receiving the best prevention possible for RSV.
Synagis (palivizumab) is indicated for the prevention of serious lower respiratory tract disease caused by respiratory syncytial virus (RSV) in children at high risk of RSV disease.
Indications:
Synagis is the only FDA-approved monoclonal antibody to help protect high-risk infants against RSV.
Synagis palivizumab 100mg/1 mL Single-Dose Vial is a highly effective medication used to prevent serious respiratory infections in infants and young children caused by the respiratory syncytial virus (RSV). RSV is the most common cause of bronchiolitis and pneumonia in children under the age of one, making it a significant health concern for parents and healthcare providers. Synagis works by targeting the RSV virus and preventing it from replicating, therefore reducing the risk of severe lung infections. This medication has been shown to significantly reduce hospitalizations and even deaths in premature infants and children with lung or heart conditions. Its convenient single-dose vial form makes it easy to administer and its recommended dosage of once a month for a total of 5 doses during RSV season offers excellent protection. The benefits of Synagis palivizumab 100mg are clear, as it not only protects against potentially life-threatening infections, but also provides peace of mind for parents knowing their child is receiving the best prevention possible for RSV.
Synagis (palivizumab) is indicated for the prevention of serious lower respiratory tract disease caused by respiratory syncytial virus (RSV) in children at high risk of RSV disease.
Indications:
Something went wrong. Please try again.
Check your email for exclusive offers and updates from Mountainside Medical.